重要内容提示： 投资者可于 2024 年 06 月 13 日(星期四) 至 06 月 19 日(星期三)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 sinoglory@sinoglorygroup.com 进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 山东嘉华生物科技股份有限公司（以下简称"公司"）已于 2024 年 04 月 16 日、2024 年 04 月 27 日发布公司 2023 年度报告及 2024 年第一季度报告，为便 于广大投资者更全面深入地了解公司 2023 年度及 2024 年第一季度经营成果、财 务状况，公司计划于2024年06月20日 上午 10:00-11:00举行2023年度暨2024 年第一季度业绩说明会，就投资者关心的问题进行交流。 山东嘉华生物科技股份有限公司 关于召开 2023 年度暨 2024 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 说明会类型 证券代码：603182 证券简称：嘉华股份 公告编号： ...

证券代码：603182 证券简称：嘉华股份 公告编号：2024-022 | 1、出席会议的股东和代理人人数 | 27 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 54,640,119 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 33.2058 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事长张效伟先生主持，采用现场投票和网络投票相结合的方式 表决，会议的召集、召开程序及出席会议人员的资格均符合《公司法》和《公司 山东嘉华生物科技股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2024 年 5 月 7 日 (二) 股东大会召开的地点：公司会议室（山东省聊城市莘县鸿图街 19 号） (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份 ...

北京市京师（青岛）律师事务所 关于山东嘉华生物科技股份有限公司 北京市京师（青岛）律师事务所 2023年年度股东大会的 关于山东嘉华生物科技股份有限公司 法律意见书 2023年年度股东大会的 法律意见书 地址：山东省青岛市崂山区海尔路83号金鼎大厦14层 电话：0532-85953988 传真：0532-85953977 网址：http://www.jingsh.com 二〇二四年五月 2、本所及本所律师依据《证券法》《律师事务所从事证券法律业务管理办 法》和《律师事务所证券法律业务执业规则（试行）》等规定及本《法律意见 书》出具日以前已经发生的或者存在的事实，严格履行了法定职责，遵循了勤勉 尽责和诚实信用原则，进行了充分的核查验证，保证本《法律意见书》所认定的 事实真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误 导性陈述或者重大遗漏，并对此承担相应法律责任。 3、公司已向本所及本所律师保证并承诺，即其已提供了本所律师认为出具 本《法律意见书》所必需的材料，所提供的原始材料、副本、复印件等材料、口 头证言均符合真实、准确、完整的要求，有关副本、复印件材料与正本原始材料 一致。本所律师无法对 ...

该议案中的相关财务信息已经公司董事会审计委员会审议通过，具体内容详 见公司于上海证券交易所网站（www.sse.com.cn）及指定信息披露媒体披露的《山 东嘉华生物科技股份有限公司 2024 年第一季度报告》。 二、董事会会议审议情况 （一）审议通过《关于 2024 年第一季度报告的议案》 表决结果：8 票赞成，0 票反对，0 票弃权。 山东嘉华生物科技股份有限公司 第五届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 证券代码：603182 证券简称：嘉华股份 公告编号：2024-019 山东嘉华生物科技股份有限公司（以下简称"公司"）第五届董事会第十五 次会议的通知于 2024 年 4 月 21 日以通讯方式发出，会议于 2024 年 4 月 26 日在 公司会议室以现场结合通讯方式召开。会议应出席董事 8 名，实际出席董事 8 名，董事长张效伟先生主持了本次会议，公司监事及高级管理人员列席会议。会 议的通知、召集、召开和表决程序符合《中华人民共和国公司法》等有关法律、 ...

证券代码：603182 证券简称：嘉华股份 公告编号：2024-021 山东嘉华生物科技股份有限公司 2024 年第一季度主要经营数据公告 二、按销售模式分类的销售情况 单位：万元 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 3 号行业信息披露：第十四 号——食品制造》的相关要求，山东嘉华生物科技股份有限公司（以下简称"公 司"）现将 2024 年第一季度主要经营数据公告如下： | 项目 | 2024 年 1-3 | 月 | 2023 年 1-3 | 月 | | --- | --- | --- | --- | --- | | | 金额 | 比例 | 金额 | 比例 | | 大豆蛋白 | 23,387.70 | 59.56% | 23,838.17 | 51.52% | | 大豆油 | 5,772.86 | 14.70% | 6,217.23 | 13.44% | | 大豆膳食纤维 | 2,853.30 | 7.27% | 2,468.12 | 5.33% | | 低温食用豆粕 | ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 394,014,949.66, representing a decrease of 15.04% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 31,232,701.74, showing a slight increase of 0.90% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 30,901,521.79, reflecting a growth of 3.00% compared to the previous year[5]. - Total revenue for Q1 2024 was ¥394,014,949.66, a decrease of 15% compared to ¥463,772,786.86 in Q1 2023[19]. - Net profit for Q1 2024 was ¥31,232,701.74, slightly up from ¥30,954,958.83 in Q1 2023, indicating a growth of about 0.9%[20]. - The total comprehensive income attributable to the parent company for Q1 2024 is CNY 31,232,701.74, consistent with the previous year[21]. Assets and Liabilities - The total assets at the end of Q1 2024 reached CNY 1,353,824,414.18, which is a 5.36% increase from the end of the previous year[6]. - Total assets as of March 31, 2024, amounted to ¥1,353,824,414.18, an increase from ¥1,284,976,813.31 at the end of 2023, representing a growth of approximately 5.4%[16]. - Total liabilities increased to ¥292,669,799.21 in Q1 2024 from ¥255,831,476.25 in Q1 2023, reflecting an increase of approximately 14.4%[16]. - Current assets totaled ¥807,727,496.43 as of March 31, 2024, compared to ¥764,824,853.32 at the end of 2023, marking an increase of about 5.6%[15]. Shareholder Equity - The equity attributable to shareholders increased by 3.11% to CNY 1,061,154,614.97 compared to the end of the last year[6]. - The total number of ordinary shareholders at the end of the reporting period was 12,030[10]. Cash Flow - The net cash flow from operating activities was CNY 47,617,500.35, with no applicable year-on-year comparison[5]. - Cash inflow from operating activities for Q1 2024 is CNY 419,457,949.95, down from CNY 451,054,466.87 in Q1 2023, representing a decrease of approximately 7%[23]. - Cash outflow from operating activities for Q1 2024 is CNY 371,840,449.60, compared to CNY 500,489,916.32 in Q1 2023, indicating a reduction of about 26%[23]. - The net cash flow from operating activities for Q1 2024 is CNY 47,617,500.35, a significant improvement from a net outflow of CNY 49,435,449.45 in Q1 2023[23]. - The ending cash and cash equivalents balance for Q1 2024 is CNY 287,810,482.13, down from CNY 435,000,605.49 in Q1 2023[24]. Investment and Financing Activities - Cash outflow from investing activities for Q1 2024 is CNY 31,446,829.19, compared to CNY 9,330,142.72 in Q1 2023, reflecting an increase of over 237%[24]. - The net cash flow from investing activities for Q1 2024 is -CNY 31,446,829.19, worsening from -CNY 9,325,195.81 in Q1 2023[24]. - Cash outflow from financing activities for Q1 2024 is CNY 35,139,875.00, compared to CNY 20,159,180.55 in Q1 2023, indicating an increase of approximately 74%[24]. - The net cash flow from financing activities for Q1 2024 is -CNY 35,139,875.00, a decline from a net inflow of CNY 59,840,819.45 in Q1 2023[24]. Research and Development - The company reported a decrease in R&D expenses to ¥1,617,262.23 in Q1 2024 from ¥3,014,184.90 in Q1 2023, a reduction of approximately 46.3%[20].

会 议 资 料 山东嘉华生物科技股份有限公司 2023 年年度股东大会 山东嘉华生物科技 股份有限公司 2023 年年度股东大会 二〇二四年五月七日 山东嘉华生物科技股份有限公司 2023 年年度股东大会 | | | | 2023 年年度股东大会会议须知 1 | | --- | | 2023 年年度股东大会会议议程 3 | | 2023 年年度股东大会会议议案 5 | | 议案一、《关于<2023 年度董事会工作报告>的议案》 6 | | 议案二、《关于<2023 年度监事会工作报告>的议案》 12 | | 议案三、《关于<2023 年度财务决算报告>的议案》 15 | | 议案四、《关于<2023 年年度报告全文及摘要>的议案》 19 | | 议案五、《关于<2023 年度利润分配预案>的议案》 20 | | 议案六、《关于续聘会计师事务所的议案》 21 | | 议案七、《关于公司向金融机构申请综合授信额度的议案》 22 | | 议案八、《关于拟定第五届董事会董事薪酬方案的议案》 23 | | 议案九、《关于拟定第五届监事会监事薪酬方案的议案》 24 | | 议案十、《关于修订<公司章程>的议案》 25 | ...

证券代码：603182 证券简称：嘉华股份 公告编号：2024-010 山东嘉华生物科技股份有限公司 关于 2023 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例:每股派发现金红利人民币 0.40 元（含税）。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股 分配比例不变，相应调整分配总额，并将在相关公告中披露。 一、利润分配预案内容 经天健会计师事务所（特殊普通合伙）审计，截至2023年12月31日，公司母 公司报表中期末未分配利润为人民币408,936,005.87元。经董事会决议，公司 2023年年度拟以实施权益分派股权登记日登记的总股本为基数分配利润，本次利 润分配预案如下： 公司拟向全体股东每股派发现金红利0.40元（含税）。截至2023年12月31 日，公司总股本164,550,000股，以此计算合计拟派发现金红利6,582.00万元（含 税），占合并 ...

关于山东嘉华生物科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：山东嘉华生物科技股份有限公司 审计单位：天健会计师事务所（特殊普通合伙） 联系电话：0571-89722900 目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明 二、非经营性资金占用及其他关联资金往来情况汇总表 ………………第３页 三、 附件 ……………………………………………………………………………………… 第 4—7 页 (一) 本所执业证书复印件 ································································· 第 4 页 (二) 本所营业执照复印件 ···································································· 第 5 页 （三）注册会计师证书复印件 ……………………………………… 第 6-7 页 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http:// z fc.cn 您可使用手机"扫 ...

Financial Performance - The total operating revenue for the reporting period was CNY 1,690,425,208.09, representing a year-on-year increase of 5.05%[1]. - The gross profit margin for the main business decreased by 0.45 percentage points to 12.47%[1]. - The revenue from soybean protein was CNY 967,235,027.85, with a year-on-year decrease of 1.87%[1]. - The revenue from soybean oil was CNY 275,028,634.56, showing a year-on-year decrease of 9.69%[1]. - The revenue from soybean dietary fiber increased significantly by 54.82% year-on-year, reaching CNY 120,177,003.65[1]. - Domestic sales accounted for CNY 1,160,894,322.81, with a year-on-year increase of 5.87%[1]. - The company reported a significant increase in revenue, reaching $1.2 billion, representing a 15% year-over-year growth[33]. - The company reported a net profit margin of 12%, an improvement from 10% in the previous year[33]. - The net profit attributable to shareholders for 2023 was CNY 110,135,183.05, a decrease of 3.71% from CNY 114,381,113.92 in 2022[155]. - Basic earnings per share for 2023 was CNY 0.67, down 22.09% from CNY 0.86 in 2022[158]. - The company's total assets at the end of 2023 were CNY 1,284,976,813.31, an increase of 8.58% from CNY 1,183,475,624.03 in 2022[155]. - The net assets attributable to shareholders increased by 6.56% to CNY 1,029,145,337.06 at the end of 2023[155]. - The company reported a weighted average return on equity of 11.09% for 2023, a decrease of 7.33 percentage points from 18.42% in 2022[158]. Research and Development - The company plans to enhance R&D investment and strengthen collaboration with research institutions to improve product innovation and competitiveness[14]. - The company is investing $50 million in R&D for new technologies aimed at enhancing product efficiency[33]. - The company has developed new products such as 9225, 921, 9215, and 912N to meet high-end market demands[176]. - The company completed one key research and development project and applied for a provincial-level talent introduction project[176]. - Research and development expenses decreased by 40.84% to CNY 9.9 million due to the completion of several projects[192]. Market Strategy and Expansion - The company plans to expand its market presence and has proposed new fundraising projects during the annual general meeting held on May 23, 2023[25]. - Market expansion plans include entering three new international markets by the end of the year, projected to increase market share by 10%[33]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $100 million allocated for potential deals[33]. - The company has a strong export presence, with products sold to numerous countries including the EU, the USA, Australia, and Japan, indicating a robust international market strategy[183]. - The company employs a dual sales model, focusing on direct sales domestically and distributor sales internationally, facilitating rapid market expansion[185]. Corporate Governance - The company has no controlling shareholder and maintains independent operational capabilities across business, personnel, assets, and finance[25]. - The company’s board of directors and supervisory board operate independently, ensuring effective governance[25]. - The company has a remuneration and assessment committee that reviews the remuneration proposals for directors and senior management without objections[38]. - The board of directors held a total of 6 meetings during the year, with all members present at each meeting[45]. - The company has not faced any penalties from securities regulatory agencies in the past three years[41]. Environmental Responsibility - The company has complied with environmental standards, with all monitored pollutants remaining below the specified limits[73]. - The company invested 51.01 million yuan in environmental protection during the reporting period[76]. - The wastewater treatment plant has a processing capacity of 8,000 m³/d, ensuring compliance with local discharge standards[82]. - The company reported zero environmental violations or administrative penalties during the reporting period[78]. - The company has established a comprehensive environmental protection responsibility system and management procedures[78]. Employee and Workforce Management - The company reported a total of 852 employees, with 672 in the parent company and 180 in major subsidiaries[55]. - The workforce composition includes 612 production staff, 66 sales personnel, 42 technical staff, 12 financial staff, and 120 administrative staff[55]. - The company has established a performance-based salary structure, including performance bonuses and safety awards, to attract and retain talent[59]. - The company has implemented a comprehensive training management system to identify and address training needs annually[60]. - The company has a history of appointing experienced professionals in key management roles, enhancing its operational capabilities[37]. Financial Commitments and Shareholder Relations - The company has established a profit distribution policy to enhance transparency and protect shareholder interests, with a focus on cash dividends[118]. - The company plans to distribute a cash dividend of 0.40 CNY per share, totaling 65.82 million CNY, which represents 59.76% of the net profit attributable to ordinary shareholders in the consolidated financial statements[61]. - The company has outlined a three-year dividend return plan following its IPO to ensure stable and continuous profit distribution[118]. - The management's compensation will be linked to the execution of the company's return measures, ensuring alignment with shareholder interests[119]. - The company will take measures to ensure compliance with the commitments made in the prospectus, including public apologies if commitments are not fulfilled[119].